Toxicity of levodopa in parkinson disease therapy
Parkinson's disease is a universal progressive neurological disease, being a more common neurodegenerative disease in the population between 58 and 69 years old. It is constituted as a disease by the degeneration of the black base substance, where a dopamine is synthesized, associated to the presence of cytoplasmic molecules formed by the accumulation of proteins such as Lewy corpuscles. The choice of treatment depends on the functional deficit and response to the treatment already used.